NCT00620139|Completed
Loading search results
Sponsor study identifier
observational
17
1 country
1
Study Start
March 2005
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
October 2013
Actual (reported)Study Completion
October 2013
Actual (reported)This pilot study seeks to evaluate the feasibility of measuring the proximal effects of concurrent chemoradiotherapy (CRT) on the expression of potential therapeutic target molecules in Head and Neck Squamous Cell Carcinoma (HNSCC). Specifically, this study proposes to evaluate the extent to which CRT induces the differential expression of components along two critical, and potentially interdependent, molecular pathways: the arachidonic acid and epidermal growth factor receptor (EGFR) signaling pathways.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
October 2013
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
March 2005
Date type not reportedThis date has not been verified as actual or estimated.
January 25, 2008
Actual (reported)February 21, 2008
Actual (reported)October 2013
Actual (reported)October 2013
Actual (reported)To evaluate the proximal effects of concurrent chemoradiotherapy (CRT) on the expression of potential therapeutic molecular targets along the arachidonic acid and epidermal growth factor receptor (EGFR) signaling pathways in HNSCC.
Conclusion of the study
Some patients presenting with suspicious lesions of the oropharynx or oral cavity will need to undergo transoral biopsy in the clinic to confirm the diagnosis of carcinoma. Of those patients who choose to participate in the study, an extra piece of tumor will be harvested for investigational purposes related to this trial.
patient will undergo transoral pretreatment biopsy of the tumor. A comparable second tumor biopsy will be performed in the office after exactly 5 days of concurrent CRT (5 daily fractions of 180-200 cGy radiotherapy and a single cycle of Cisplatin or Carboplatin/5-FU based chemotherapy).Blood plasma and single-void urine specimens will be collected contemporaneously,before and after 5 days of concurrent CRT.
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
MSKCC clinics
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
Urine Blood Tissue
Nancy Lee, MD
Memorial Sloan Kettering Cancer Center
17 participants (actual enrollment reported by the registry).
First Submitted
January 25, 2008
First Posted
February 21, 2008
Study Start
March 2005
Date type not reportedThis date has not been verified as actual or estimated.
A Study of the Use of Fat Flap Reconstruction to Reduce Neck Injury After Cancer Treatment
Contact the study team to confirm eligibility.
Primary Completion
October 2013
Actual (reported)Study Completion
October 2013
Actual (reported)Last Updated
October 24, 2013
Record last verified: 2013-10
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: